Objective: To evaluate the effectiveness and safety of insulin detemir treatment as add-on therapy in a real-world setting of Lebanese insulin naïve persons, with type 2 diabetes poorly controlled on oral antidiabetic drugs (OADs).
Original Report:
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IntroductIon
Developing countries from the Near East region face a serious socioeconomic burden related to the rising trend in the prevalence of diabetes. In particular, the International Diabetes Federation reports a 14.53% prevalence of diabetes in Lebanon in 2013. 1 In parallel, the availability of local clinical data is essential to increase awareness and provide appropriate guidance on the management of type 2 diabetes mellitus (T2DM). 2 A substantial number of persons with T2DM needs insulin therapy after 9 years or more of disease due to unremitting loss of β-cell function with a need of intensification to a basal-bolus insulin regimen after 3-5 years of basal insulin treatment. 3, 4 The timely addition of insulin to oral antidiabetic (OADs) agents is a key step in the management of these patients. It prevents the chronic complications of diabetes through glycemic control, and aids in adapting to the progressive β-cell failure caused by extended exposure to hyperglycemia. [5] [6] [7] The results of the United Kingdom Prospective Diabetes Study (UKPDS) 5 allowed the American Association of Clinical Endocrinologists (AACE) to set a target glycosylated hemoglobin A1c (HbA1c) of ≤6.5%, 7 and the American Diabetes Association (ADA) to recommend an HbA1c level <7%. 8 However, although the efficacy and safety of insulin therapy in T2DM are well-established, guide-
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In persons wIth type 2 DIabetes In near east CountrIes: results from the lebanese subgroup Insulin detemir in T2DM -Echtay et al lines and clinical practice differ in the timely initiation of insulin. 9 Further, hypoglycemia is the main restricting factor in insulin dependent glycemic management. Other hurdles to insulin therapy are: physical and psychosocial morbidity; mortality; 10 individual and physician concerns about weight gain; 5, 6, 11, 12 possibility of insulin-associated atherogenicity; injection-site pain; and economic considerations. 5, 11, 12 In parallel, insulinotherapy is pivotal in the management of T2DM, but no consensus exists about the best ways to overcome the aforementioned barriers when initiating insulin therapy. 13, 14 The addition of a long-acting basal insulin formulation to an existing OAD regimen, followed by aggressive titration of the dose to achieve glycemic targets has gained popularity in recent years. It has also been recommended in the recent guidelines and targets for glycemic control published by IDI, 13 and ADA-EASD 15 as a simple treat-to-target approach, following its success in clinical trials. [13] [14] [15] [16] [17] [18] The development of long-acting basal insulin analogues with improved pharmacokinetics, which are able to more closely mimic endogenous insulin secretion, has been shown to have a positive effect on the balance between effective glycemic control and hypoglycemic risk. 19 Two bioengineered basal insulin analogues, including insulin glargine and insulin detemir, have been found to enable this treat-to-target approach with a reduced risk for hypoglycemia compared with that found with a conventional, human insulin-based formulation, neutral protamine Hagedorn (NPH). [15] [16] The analogue insulin detemir (IDet) belongs to a new class of non-crystalline form of long-acting insulin analogs. 20 It has more reproducible absorption and a prolonged time-action profile, 21 besides a less within-people variability for the pharmacodynamic endpoints compared with NPH insulin and insulin glargine. 20 It also offers a better reproducibility as compared with stringently monitored in the real clinical practice, and the general patient population is more diverse than those in clinical trials. 23 In this context, our study aimed to evaluate the effectiveness and safety of 24-week insulin detemir treatment administered as add-on therapy in a realworld setting of OAD-treated, insulin naïve, T2DM Lebanese persons.
Methods
Study Design and Population
Our study represents the Lebanese arm of a prospective, multicenter, multinational, 24-week observational study conducted across the Near East countries of Lebanon, Jordan, Pakistan and Israel. The multinational study (NCT00842192) involved 2,155 participants from the Near East.
In Lebanon, inclusion criteria were persons with T2DM who were newly diagnosed or previously treated with one or more OADs (metformin, sulfonylureas, repaglinide, thiazolidinediones) and were starting insulin detemir with or without OAD therapy. Persons who were being treated with insulin detemir or any other insulin, persons with a hypersensitivity to insulin detemir or to any of the excipients, women who were pregnant, breast feeding, having the intention of becoming pregnant within next 6 months, or of childbearing potential who were not using adequate contraceptive methods were excluded from the study.
Eligible persons were recruited from primary and secondary care settings across the country from other basal insulins, reduces the risk of hypoglycemia, 20 and causes little or no weight gain. 22 It may lead patients to titrate their insulin doses more easily and, therefore, to more often achieve glycemic objectives. 20 Importantly, achieving blood glucose control is a known prerequisite for improving an individual's outcomes in T2DM. Relevant clinical studies focus on a treatment's ability to achieve glycemic targets during strictly enforced regimens.
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April 2009 to August 2010. Selection of study participants was at the discretion of the individual physician. As participants were not randomized in this study, allocation of personal identification was accomplished by unique person numbers.
Data Collected
The participants' demographic data, past history of T2DM, and the reason for adding on insulin detemir were first collected. Then, effectiveness parameters were collected: determination of glycemic control by identifying the level of HbA1c, fasting plasma glucose (FPG), variability in FPG, post-prandial plasma glucose (PPG) levels, persons achieving target of HbA1c of <7%, insulin therapy and OAD therapy. Safety parameters were also reported: hypoglycemic episodes, adverse drug reactions (ADRs), serious ADRs (SADRs) and body weight.
These parameters were recorded for the entire observation period at routinely scheduled three consecutive clinic visits conducted at week 0 (baseline visit), week 12 (interim visit) and week 24 (final visit). Data for safety and effectiveness parameters were collected from the participants' records, recall and diaries. Data on measurement of all study parameters (either at the clinic or self-reported) depended on routine practice. This was believed to be consistent for each participant at the baseline as well as the scheduled visits.
Study Endpoints
The primary effectiveness endpoint was change in HbA1c from baseline to 12 and 24 weeks. Secondary endpoints were assessed at 12 and 24 weeks of treatment compared with baseline: percentage of participants achieving HbA1c <7% and ≤6.5%, glucose variability measured as change in FPG, postprandial glycemic control measured as change in PPG, change in insulin dose and oral OAD therapy.
The primary safety endpoint was change in number of hypoglycemic episodes from the 4 weeks preceding the baseline visit compared with after 12 and 24 weeks of IDet treatment. Information on hypoglycemic episodes was collected based on participant's recall of the last 4 weeks before baseline, weeks 12 and 24. Secondary safety endpoints were the number of ADRs and change in body weight after approximately 12 weeks and 24 weeks of treatment compared to baseline.
A hypoglycemic event was defined as an event with one of the following characteristics: 1) symptoms of hypoglycemia that resolve with oral carbohydrate intake, glucagon or intravenous glucose or any symptomatic or asymptomatic plasma glucose <3.11 mmol/l; 2) nocturnal hypoglycemic events were defined as individualized symptomatic events consistent with hypoglycemia, that occur while the patient is asleep, between bedtime after the evening insulin injection and before getting up in the morning (if relevant, before morning determination of FPG and before morning injection). Major hypoglycemic events were defined as events with severe central nervous system symptoms consistent with hypoglycemia in which the participant was unable to treat himself/herself and had a plasma glucose <3.11 mmol/l, or reversal of symptoms after either glucagon or intravenous glucose administration.
Treatment Regimen
Insulin detemir was introduced to participants already receiving one or more OADs (biguanides, repaglinide, thiazolidinediones, sulfonylureas, or alpha-glucosidase-inhibitors).
The OAD+insulin regimen was initiated for the newly diagnosed patients by the treating physician as part of routine clinical care. The starting dose and subsequent adjustments of the treatment regimen were at the individual physician's discretion. Insulin detemir was administrated according to the approved label.
The clinical supplies coordination did not provide any products or devices for this trial as commercially available OADs and insulin detemir were used in this observational study. Insulin detemir (Levemir®) available as 3 mL Penfill â cartridges (100 U/mL) or 3 mL FlexPen ® devices (100 U/mL, 5 FlexPen ® devices/package) was prescribed.
Statistical Analysis
With a statistical power >99% to detect a 1% change in HbA1c from baseline, a standard deviation of 1.2 and an estimated drop-out rate of 20%, 2,000 persons from the 4 participating countries were considered sufficient to evaluate primarily the safety of IDet; approximately 900 persons participated from Lebanon.
Demographic and clinical characteristics were summarized using means and standard deviations for continuous variables and frequency and percentages for categorical vari-
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ables. Statistical analysis was performed using paired t-tests for continuous variables and chi-square test for categorical data. Missing data were reported when appropriate. Statistical analysis was based on two-sided tests with a significance level of 5%.
The safety analysis set comprised all participants who had received at least one dose of insulin detemir. The full analysis set (FAS) comprised all participants who had received at least one dose of insulin detemir and had any post-baseline data. The effectiveness analysis set (EAS) comprised all participants in FAS who had a final visit at week 24 and at least one measurement concerning FPG, PPG, most recent HbA1c, weight or hypoglycemic episodes at baseline and final visit.
Statistical analysis was performed using SAS version 9.1.3. (SAS® Institute Inc., Cary, North Carolina, USA).
Ethical Considerations
The study was approved by the ethics committee of each participating center. It was performed in accordance with the regulatory requirements for observational studies in Lebanon, and the Declaration of Helsinki. All participants completed an informed consent form before their enrollment.
results
Participants' Disposition and Demographics
894
Lebanese participants were initially enrolled, 815 persons (91.2%) completed the study due to withdrawal of 53 persons, loss of contact (n=45) and other reasons (n=8). Thus, FAS and safety analysis sets were composed of 868 (97.1%), while EAS included 814 (91.1%) participants.
The mean age of the 868 participants was 59.5 ± 10.4 years, 55.3% were men. In 95% of the cases, the main reason for starting insulin detemir was to improve glycemic control. Participants' demographics and reasons for adding insulin detemir are displayed in Table 1 .
Primary Effectiveness Results
Glycemic control improved as the mean HbA1c was significantly reduced from 9.7 ± 1.6% at baseline to 7.8 ± 1.0% at week 12 and to 7.2 ± 1.0% at week 24 (P<.0001) ( Table 2) .
Secondary Effectiveness Results
In the FAS, the percentage of participants who achieved the target of HbA1c <7% increased from .7% at baseline to 17.8% at week 12 and 39% at week 24. The percentage of participants who achieved the target of HbA1c of <6.5% increased from .4% to 5.8% at week 12 and 17.4% at week 24. Similarly, in the EAS, the percentage of participants who achieved the target of HbA1c of <7% increased from .8% at baseline to 18.2% at week 12 and 39% at week 24. The percentage of participants who achieved the target of HbA1c of <6.5% increased from .4% to 5.8% at week 12 and 17.4% at week 24.
Mean FPG levels were reduced from 213.7 ± 60.1 mg/dL at baseline to 120.3 ± 25.7 mg/dL at week The mean daily dose of insulin detemir exposure was increased from 17.5 ± 7.4 U at baseline to 25.6 ± 10.1 U at week 12 and to 27.7 ± 10.8 U at the end of the study. Insulin detemir dosage per body weight was .22 ± .1 U/Kg at baseline, .32 ± .12 U/Kg at week 12 and .34 ± .13 U/Kg at week 24.
Biguanides (76.5%) and sulfonylureas (74.7%) were the most commonly prescribed OADs at baseline. After 12 weeks of treatment, the 
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first two commonly received OADs were biguanides (78.9%) and sulfonylureas (70.1%). At the end of 24 weeks of treatment, the proportion of participants using biguanides increased minimally (78.8%) while that of sulfonylureas (67.5%) decreased compared with baseline (Table 2) .
PrIMary safety results
The rate of total hypoglycemic episodes slightly decreased from 2.0069 at baseline to 1.8556 per person year at week 24, while the rate of major hypoglycemic episodes decreased from .1498 at baseline to .0448 per person year at week 24. The rate of daytime major hypoglycemic episodes decreased from .0749 at baseline to .0320 at week 24, while the rate of nocturnal major hypoglycemic episodes decreased from .0749 at baseline to .0128 per person year at week 24. The rate of total hypoglycemic episodes due to fasting regimen slightly increased from .0449 at baseline to .1280 per person year at week 24. No major hypoglycemic episodes due to fasting regimen were reported at baseline or week 24 (Table 3) .
Secondary Safety Results
No ADRs, SADRs and serious adverse events (SAEs) were reported in Lebanese participants. A total of 3 moderate adverse events (AEs) (2 recovered, 1 recovering) were recorded in 2 participants (.2%) with reduction in dose (n=1), increase in dose (n=1) and no change in the dose (n=1).
Body weight was 80.4 ± 13.2 Kg at baseline, 80.1 ± 12.9 Kg at week 12 and significantly decreased to 79.9 ± 12.5 at week 24 compared with baseline value (P<.0001).
dIscussIon
Our study assessed the effectiveness and safety of 24-week insulin detemir administered as add-on therapy in a real-world setting of OAD-treated, insulin naïve, T2DM kg, P<.01) and insulin glargine (.5 kg, P<.05) to insulin detemir, as per the 14-week follow-up data of PRE-DICTIVE™ study. 25 Likewise, an average weight loss of .9 kg (P<.0001) was observed in a German subgroup of the PREDICTIVE™ study, with T2DM transferred to insulin detemir ± OADs from an OAD-only regimen, NPH insulin ± OADs, or insulin glargine ± OADs. 26 Given the global increase in obesity rates, 27 the finding that insulin detemir reduces weight gain in persons with T2DM makes it clinically advantageous compared with other available forms of insulin. 28 However, the weight loss could be attributable to reduced insulin requirements in the Lebanese patients who were on oral agents, in addition to certain lifestyle modifications such as improved diet and increased exercise.
The investigators mainly initiated insulin detemir as add-on therapy to improve glycemic control both in the Lebanese population and overall population evaluated in the multinational analysis of the study. However, sequence of other reasons for initiating therapy varied between the two populations. As such, the reduction in blood glucose variability, person dissatisfaction with current therapy and unstable diabetes were more prominent in the Lebanese participants. In contrast, the reduction of the risk of hypoglycemia and the improvement of weight control were more common reasons for initiating insulin detemir therapy in the overall study population. Moreover, the combination of insulin detemir with OADs showed to be safe with no ADRs/SAEs. Hence, insulin de-
Effective glycemic control was achieved with lower incidence of major hypoglycemic events and no significant weight gain.
persons with suboptimal baseline glycemic control (HbA1c=9.7%) or with baseline blood glucose levels beyond recommended glycemic targets (FPG=213.7 ± 60.1 mg/dL, PP=271.0 ± 65.3 mg/dL).
Effective glycemic control was achieved with lower incidence of major hypoglycemic events and no significant weight gain. While weight gain is a prime concern in the first year of initiating insulin therapy in T2DM, 5, 6 insulin detemir seemed to overcome this barrier in our study. Indeed, it reduced overall body weight by .5 kg after 24 weeks of treatment, while it was weight neutral according to the multinational results. 24 A significant weight loss was also observed in patients transferred from NPH insulin (.7
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temir plus OAD therapy seemed to meet the therapeutic expectations.
To reach a target HbA1c <7% using basal insulin plus OADs, the basal insulin should be initiated before HbA1c rises above 8.5%. In this sense, the mean level of overall HbA1c reduction found in studies investigating the addition of basal insulin to OADs was reported to be approximately 1.5%. 29 Accordingly, the effectiveness of insulin detemir for reducing baseline HbA1c in the Lebanese population by -2.5% (from 9.7 to 7.2%) was in line with the literature. It was also slightly better than multinational results in the four Near East countries (from 9.6 to 7.6; -2.0%), 24 indicating significantly improved glycemic control. When also compared with multinational results, reduction of the percentage of persons with HbA1c <7% was more pronounced in the Lebanese population both at weeks 12 (17.8% vs 13.2%) and 24 (26.9% vs 39%). Accordingly, a reduction of HbA1c of <7% is notable in a higher number of Lebanese patients since the mean HbA1c at baseline was 9.7%. The latter indicates a need for a more aggressive insulin regimen in a greater number of persons to achieve the desired HbA1c target. While HbA1c continued to fall, the achievement of greatest improvement in FPG at 12 weeks was suggested to indicate optimization of insulin detemir regimens within this timeframe with subsequent improvements in glycemic control made by adjusting prandial glucose. 13 The incidence of major hypoglycemic events (overall, daytime, nocturnal) decreased in our study population, consistently with the multinational results. 24 This finding is encouraging as hypoglycemia remains one of the most disturbing side effects of insulin use. 10 Also, the achievement of a mean HbA1c of 7.2% at the end of study in the Lebanese population indicates less likelihood of hypoglycemia and is consistent with other studies. The introduction of long-acting insulin analogues minimized the risk of hypoglycemia, especially nocturnal episodes. 15, 16 This difference with interventional studies can be explained by the nature of observational studies and the diabetes monitoring habits of Lebanese persons. First, observational studies have the advantage of studying large and heterogeneous populations. However, they have some limitations, such as a lack of control groups, potential person recall bias and possible variations in clinical practice between countries. Second, self-monitoring habits may be different across countries and may affect the glycemic control and hypoglycemia rates. 30 Indeed, a 24-week insulin detemir treatment was determined to have a promising safety profile based on the reduction in all types of major hypoglycemic episodes, in addition to the reporting of only three AEs in two persons, no ADRs nor SAEs. Similarly, the incidence of SADRs (0%) and ADRs (.4%) with insulin detemir treatment was indicated to be minimal at the end of 24-week treatment in the multinational results. 24 Given that insulin detemir was also associated with a low incidence of SADRs and ADRs in the Lebanese population, the safety data obtained in our study support past clinical studies indicating that the new basal analogue insulin detemir incurs low incidence of SADRs and ADRs. 24, 31 They also suggest a low/similar risk of hypoglycemia, with less weight gain at equivalent levels of glycemic control compared with NPH insulin 12 or insulin glargine 16, 22 when used as either an adjunct to oral therapy or as part of basal-bolus therapy. 12 Not only a low incidence of safety events and no significant weight gain were reported for insulin detemir ± OADs in our 24-week treatment period, similar results were also found throughout the 52-week treatment period. 12, 28 Nevertheless, considering insulin detemir for those persons who may be more vulnerable than those recruited into clinical trials seems reasonable. 12 Although clinical trials support flexibility in injection frequency (once or twice daily), the pharmacodynamics profile of insulin detemir is best suited to once-daily use in persons with T2DM. 32 While data on frequency of injections was not collected in this study, similar studies with insulin detemir ± OADs showed that a once-daily injection was adequate for good glycemic control in the majority of persons (77% to 82%) with <25% persons requiring twice daily injections after 14 weeks of insulin detemir ± OADs. 25, 31 Accordingly, an increase in the mean daily dose of insulin detemir from 17.5 ± .22 U/kg at baseline to 27.7 ± .34 U/kg at the end of the study in the Lebanese population is in line with the 52-week follow-up results of PREDICTIVE TM study. 27 The latter indicates that the proportion
of persons with T2DM using oncedaily insulin detemir was 67% at the end of 52-week follow-up, with a slight increase observed in dosage. 12 Likewise, considerable decrease in the proportion of persons receiving the sulfonylureas and thiazolidinediones was reported at the end of study, although the majority of the persons received biguanides, sulfonylureas and thiazolidinediones at each visit. This is consistent with the findings of international studies. 33 Hence, the advantages of insulin detemir could be of particular relevance in overcoming the barriers of insulin initiation and treatment adherence in persons.
In this regard, our findings strengthen the data on insulin detemir for glycemic control in T2DM persons associated with a minimized risk of hypoglycemia and weight gain from different person populations. 25, 32, 33 They are also consistent with clinical trial data of insulin detemir in comparison to other insulin types and can be relevant to routine clinical practice. 5, 16, 22 Consequently, insulin therapies like insulin detemir, which are better able to mimic the body's physiological responses, provide some scope for achieving an improved balance between glycemic control and treatment tolerability. This may support better person compliance and an improved quality of life when used in the primary care setting. 12 Although our data are consistent with the longitudinal analyses of 52-week data from the observational PREDICTIVE™ study, 12, 27 the first published analyses of long-term insulin detemir use in everyday practice are considered less reliable. The rationale is that observational studies are less stringently controlled than are clinical trials. For this reason, whether the advantages of insulin detemir related to improved balance between mean glycemic control and tolerability can be sustained over longer periods of treatment, needs to be further explored and clarified in ongoing studies. These should compare head-to-head treat-to-target with other long-acting basal insulins based on equitable once-daily dosing algorithms. Despite these drawbacks, observational studies have an important role to play in assessing a drug's performance in a real-world setting. 23 Our study has some limitations. First, an improvement to the study would have been randomization. Second, while our findings are representative of the Lebanese population, they cannot be generalized to other demographic regions and ethnic groups and as such, may not be applicable to clinical practice in other regions.
conclusIons
To conclude, our study reports a significant reduction in HbA1c, which is correlated with the improvement in FPG. Furthermore, the variability in FPG also decreased demonstrating improved control over glycemic excursions. Thus, our study indicates an improvement of glycemic control and an absence of no- 
